| | | | | | | | | | | |
| KOMISJA NADZORU FINANSOWEGO | |
| | | | | | | | | | | | |
|
| | Raport bieżący nr | 9 | / | 2023 | |
| |
| | | | | | | | | | | | |
| Data sporządzenia: | 2023-08-09 | | | | | | | | | |
| Skrócona nazwa emitenta | | | | | | | | | |
| MILESTONE MEDICAL | |
| | | | | | | | | | |
| Temat | | | | | | | | | | |
| The receipt of positive insurance payment for the CompuFlo Epidural System | |
| Podstawa prawna | | | | | | | | |
| Art. 17 ust. 1 MAR - informacje poufne.
| |
| | | | | | | | | | | | |
| Treść raportu: | | | | | | | | | |
| The Board of Directors of Milestone Medical Inc. (WAR: MMD, the Company", the Issuer"), today announced that it has received positive reimbursement from three commercial payers for the use of the CompuFlo Epidural System for patients who were involved in motor vehicle accidents and required the epidural procedure for pain management.
The epidural procedures were performed by Dr. Didier Demesmin, MD, an interventional pain medicine physician who is board-certified in both anesthesiology and pain medicine. He is also the medical director and founder of the University Pain and Spine Center, a private pain management clinic, and STEMMEE, an Ambulatory Surgery Center (ASC). Over the course of his career, Dr. Demesmin has performed thousands of epidural procedures in both the lumbar and thoracic regions of the spine and has commenced use of the CompuFlo Epidural System.
The Board of Directors of the Company believes that these payments by three commercial payers are a significant achievement for the Company. It is important to note that the approval by these commercial payers was obtained for a specific use case, following a motor vehicle accident. In the opinion of the Board of Directors of the Company, although receipt of reimbursement is encouraging, and opens the door to approval for other use cases, on its own, these initial payments do not yet confer broad coverage for other epidural procedures. Reimbursement can be a time-consuming process, standard for all new medical devices. Nevertheless, it is an important validation of the technology and reimbursement strategy. The Company remains focused on advancing positive reimbursement for the CompuFlo technology amongst all payers by continuing to support the clinicians adoption and utilization of the technology in their practices. | |
| | | | | | | | | | | | |
| | | | | |
| PODPISY OSÓB REPREZENTUJĄCYCH SPÓŁKĘ | |
| Data | Imię i Nazwisko | Stanowisko/Funkcja | Podpis | |
| 2023-08-09 | Keisha Harcum | Controller | Keisha Harcum | |
| | | | | |
